The scientist behind gene-edited babies’ eyes works in Hong Kong
A Chinese scientist who set off an ethical debate five years ago with claims that he made the world’s first genetically edited babies said Tuesday that he hopes to research rare hereditary diseases in Hong Kong.
He Jiankui shocked the world in 2018 when he announced he had altered the embryos of twin girls, with many in the scientific community criticizing his work as unethical. He was convicted by a mainland Chinese court in 2019 of practicing medicine without a license and sentenced to three years in prison with a fine of 3 million yuan ($445,000).
Ten months after his release, He announced in Beijing on Tuesday that he has been granted a Hong Kong visa and is in contact with universities, research institutes, and companies in the financial hub.
He said he would consider working in Hong Kong if there is an appropriate opportunity, and that he plans to research
gene therapy for rare hereditary diseases.
“My scientific research will comply with the ethics codes and international consensus on scientific research,” he said at a brief news conference.
His announcement in 2018 sparked a global debate over the ethics of gene editing. In interviews with The Associated Press, he said he had used a tool called CRISPR-cas9 to try to disable a gene that allows HIV to enter cells in an attempt to give the babies the ability to resist AIDS.
He was released last April and was invited to speak at the University of Oxford next month. But he wrote on Twitter this month that he was not ready to talk about his experiences over the last three years and decided to cancel the visit.
He invited about six media organizations to his news conference on Tuesday but left after reading a statement for about two minutes. He did not respond to questions as he left.
In a later written response, he said he plans to form an advisory committee on ethics to vet his future work and make sure the process is open and transparent.
He said he plans to research Duchenne Muscular Dystrophy, a genetic disorder that he said often causes people to die of heart and lung failure when they are about 20 years old. No medicine can cure the disease and gene therapy may help, he said.
“We hope to use AI tools to evolve the adeno-associated virus capsids to improve the efficiency of gene therapy and largely lower the costs of gene therapy so as to make it affordable for each family,” he said.
In Hong Kong, the granting of a visa to He under a new program to woo global talent raised concerns that recipients may have criminal records.